Tiziana Life Sciences Files Patent on Combination of Nanoparticle-Actinomycin D with Anti-Interleukin-6 Receptor Monoclonal Antibody for Treatment of Coronaviruses
Tiziana Life Sciences Ltd - Common Shares (TLSA)
Company Research
Source: GlobeNewswire
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. NEW YORK and LONDON, April 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory, autoimmune and infectious diseases, announced today that it has filed a provisional patent application on the combination of nanoparticle-Actinomycin D (NP-ACT D) with anti-interleukin-6 receptor monoclonal antibody (anti-IL-6R) as a potential therapy for management of COVID-19 disease. The underlying invention concepts are based on the hypothesis that a combination of an antiviral drug controlling proliferation of COVID-19, with an anti-inflammatory agent (e.g., anti-IL-6R) suppressing a possible ‘Cytokine Storm’ may provide immediate relief to severe cases of COVID-19 patients. Actinomycin D (ACT D), an antibiotic drug approved initially for infectious diseases in the United S
Show less
Read more
Impact Snapshot
Event Time:
TLSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSA alerts
High impacting Tiziana Life Sciences Ltd - Common Shares news events
Weekly update
A roundup of the hottest topics
TLSA
News
- Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study DataGlobeNewswire
- Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million [Yahoo! Finance]Yahoo! Finance
- Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 MillionGlobeNewswire
- Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination StudyGlobeNewswire
- Tiziana Life Sciences Advances with Promising Drug Trials [Yahoo! Finance]Yahoo! Finance
TLSA
Sec Filings
- 11/1/24 - Form 6-K
- 11/1/24 - Form 424B5
- 11/1/24 - Form 6-K
- TLSA's page on the SEC website